Minerva Biotechnologies
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
40 Bear Hill Rd, Waltham, Massachusetts,...Phone Number
(781) 487-0200Website
www.minervabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Minerva Biotechnologies
Minerva Biotechnologies is dedicated to developing innovative therapies for cancer treatment and advancing stem cell technologies. The company focuses on creating cancer immunotherapies that target 80% of solid tumors and aims to prevent cancer metastasis. Additionally, Minerva's research in regenerative medicine seeks to enable pharmaceutical companies to leverage stem cell discoveries for various diseases. Their proprietary AlphaSTEM technology enhances the efficiency of induced pluripotent stem cell generation and differentiation.Explore more
Minerva Biotechnologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Minerva Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Minerva Biotechnologies is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Minerva Biotechnologies
Click to see if Minerva Biotechnologies had a recent Job posting/layoffs
Check if Minerva Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Minerva Biotechnologies has new funding data
Product Launch: Get notified when Minerva Biotechnologies launches new products
Minerva Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Minerva Biotechnologies recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Minerva Biotechnologies as Masked Content
Find more new buyers
Compare Similar Companies to Minerva Biotechnologies
Compare insights from companies similar to Minerva Biotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Minerva Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Minerva Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Minerva Biotechnologies.
Minerva Biotechnologies financials insights
Gather financial insights about Minerva Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$2M
2020
Debt
$150K
2021
Debt
$332K
Minerva Biotechnologies Tech Stack
A closer look at the technologies used by Minerva Biotechnologies
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Minerva Biotechnologies is planning to move offices in October 2025. The move will impact approximately 20 employees at the existing office located at 40 Bear Hill Rd, Waltham, MA.
Facilities Relocation/Expansion
Person-Based
Person-Based
Left Company
Executive Move
Minerva Biotechnologies News & Media
Minerva Biotechnologies Announces Opening 1st-In-Human Phase I/II Trial of a MUC1* Targeting CAR T for Metastatic Breast Cancers at City of Hope
WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies' CAR-T targeting MUC1* opens at City of Hope for treatment of metastatic breast cancersMinerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology
WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies announces it has licensed “1XX” technology for use with its CAR T cells from Memorial Sloan Kettering Cancer CenterMinerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer
WALTHAM, Mass.--(BUSINESS WIRE)--#cart--Minerva Biotechnologies reports the FDA has approved their IND application to conduct clinical trials in breast cancer with their MUC1* CAR T cells.Minerva Biotechnologies Announces CellSystems as European Distributor of AlphaSTEM™, Naïve Stem Cell Culture System
WALTHAM, Mass.--(BUSINESS WIRE)--#stemcells--Minerva Biotechnologies Announces CellSystems as European Distributor of AlphaSTEM™, Naïve Stem Cell Culture System
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Minerva Biotechnologies
Sign Up For FreeTo access detailed company insights
Minerva Biotechnologies is dedicated to developing innovative therapies for cancer treatment and advancing stem cell technologies. The company focuses on creating cancer immunotherapies that target 80% of solid tumors and aims to prevent cancer metastasis. Additionally, Minerva's research in regenerative medicine seeks to enable pharmaceutical comp... Read More
